{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"best response of PR or CR observed within 6 months of enrollment","groups":[{"description":"SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.","id":"OG000","title":"SF1126"}],"reportingStatus":"POSTED","timeFrame":"6 months","title":"To Determine ORR","type":"PRIMARY"}